Estradiol Valerate vs Ethinylestradiol in Combined Oral Contraceptives: Effects on the Pituitary-Ovarian Axis
article
OA: bronze
CC0
⤵ 1 in-corpus citation
AI-generated summary
Combined oral contraceptives with estradiol valerate and dienogest suppressed FSH less than ethinylestradiol and dienogest, while both formulations similarly decreased AMH.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
CONTEXT: Limited studies have compared the effects of combined oral contraceptives (COCs) containing natural estrogens and synthetic ethinylestradiol (EE) on reproductive hormones. OBJECTIVE: To compare estradiol valerate (EV) + dienogest (DNG), EE + DNG, and DNG alone (active control) on levels of follicle stimulating hormone (FSH), luteinizing hormone, anti-Müllerian hormone (AMH), ovarian steroids, sex hormone binding globulin (SHBG), and the free androgen index (FAI). METHODS: This spin-off study from a randomized trial enrolled 59 healthy, 18 to 35-year-old ovulatory women, outpatients at Helsinki and Oulu University Hospitals, Finland, who were randomized to EV 2 mg + DNG 2-3 mg (n = 20); EE 0.03 mg + DNG 2 mg (n = 20); and DNG 2 mg (n = 19) for 9 weeks. Blood samples were drawn at baseline, and at 5 and 9 weeks. Age and BMI were comparable between groups; 3 women discontinued. RESULTS: EV + DNG suppressed FSH by -27% (-51% to -3%) (median [95% CI]) vs EE + DNG, -64% (-78 to -51), P = 0.04, but AMH levels decreased similarly by -9% (-18 to -0.1) vs -13% (-28 to 0.2), P = 0.38, respectively. EV + DNG increased SHBG levels by 56% (30% to 82%) and EE + DNG by 385% (313% to 423%), P < 0.001. Total testosterone decreased by 16% (-27% to -5%) in the EV + DNG group but it did not decrease in the EE + DNG group, whereas the FAI decreased by -39% (-54% to -25%) vs -72% (-78% to -67%), P < 0.001. DNG alone did not induce changes in any of these parameters. CONCLUSION: Compared with EE + DNG, treatment with EV + DNG resulted in milder pituitary downregulation and reduced induction of hepatic SHBG synthesis-potentially carrying more beneficial health effects.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (65)
- Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? via openalex
- COCs containing dienogest and 30 µg ethinylestradiol may carry a higher VTE risk compared to corresponding preparations with levonorgestrel: A meta-analysis of four large cohort studies via openalex
- Dienogest via openalex
- Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism via openalex
- Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study via openalex
- Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial via openalex
- Ethinyl estradiol vs estradiol valerate in combined oral contraceptives – Effect on glucose tolerance: A randomized, controlled clinical trial via openalex
- Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive via openalex
- Impact of estrogen type on cardiovascular safety of combined oral contraceptives via openalex
- Influence of Dienogest on Ovulation in Young Fertile Women via openalex
- Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain via openalex
- Metabolic and Haemostatic Effects of Estradiol Valerate/Dienogest, a Novel Oral Contraceptive via openalex
- Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women via openalex
- Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies via openalex
- Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest via openalex
- Preliminary Study on the Effect of Four-phasic Estradiol Valerate and Dienogest (E2V/DNG) Oral Contraceptive on the Quality of Sexual Life via openalex
- Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial via openalex
- doi:10.1016/0378-5122(82)90064-0 via openalex
- doi:10.1080/13697130500148875 via openalex
- doi:10.1046/j.1365-2141.2003.04443.x via openalex
- doi:10.1093/humrep/deh612 via openalex
- doi:10.3109/13625187.2011.614363 via openalex
- doi:10.1016/j.cca.2007.07.013 via openalex
- doi:10.1016/s0002-9378(03)00950-5 via openalex
- doi:10.1093/humupd/dmt038 via openalex
- doi:10.1210/jcem.84.10.6079 via openalex
- doi:10.1016/j.thromres.2010.01.045 via openalex
- doi:10.1080/13625187.2019.1702158 via openalex
- doi:10.1111/1471-0528.16840 via openalex
- doi:10.1016/j.ajog.2021.06.052 via openalex
- doi:10.1016/j.contraception.2017.01.001 via openalex
- W6676115632 via openalex
- doi:10.1093/humrep/dev197 via openalex
- doi:10.1016/j.fertnstert.2021.02.007 via openalex
- doi:10.1530/eje-20-0406 via openalex
- doi:10.1097/01.aog.0000559087.93476.bc via openalex
- doi:10.1111/jsm.12774 via openalex
- doi:10.1002/ijgo.12455 via openalex
- doi:10.1016/j.jsxm.2019.08.005 via openalex
- doi:10.1093/humupd/dmt062 via openalex
- doi:10.1182/blood-2003-04-1285 via openalex
- doi:10.3109/13625187.2015.1044082 via openalex
- doi:10.1016/j.contraception.2020.08.015 via openalex
- doi:10.3109/13625187.2010.504313 via openalex
- doi:10.1056/nejmoa1111840 via openalex
- doi:10.1080/13625187.2021.1988923 via openalex
- doi:10.1080/13625187.2021.1987410 via openalex
- doi:10.1089/jwh.2016.5801 via openalex
- doi:10.1016/j.contraception.2012.12.011 via openalex
- doi:10.1210/clinem/dgaa513 via openalex
- doi:10.1016/j.contraception.2012.07.008 via openalex
- doi:10.3109/00016348509157028 via openalex
- doi:10.1016/s0010-7824(02)00436-5 via openalex
- doi:10.1016/j.maturitas.2012.01.018 via openalex
- doi:10.1016/j.fertnstert.2012.11.034 via openalex
- doi:10.1016/0002-9378(82)90218-6 via openalex
- doi:10.1002/14651858.cd010813.pub2 via openalex
- doi:10.1093/humrep/des225 via openalex
- doi:10.1016/s0140-6736(80)91550-0 via openalex
- doi:10.1016/j.ajog.2005.12.007 via openalex
- doi:10.1007/s11154-011-9182-4 via openalex
- doi:10.1016/0002-9378(77)90295-2 via openalex
- doi:10.1111/j.1538-7836.2012.04720.x via openalex
- doi:10.1111/jsm.12310 via openalex
- doi:10.1016/j.rbmo.2012.09.001 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-05-14T06:40:32.549041+00:00
License: CC0
· commercial use OK